2024-11-20 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company, developing and manufacturing medicines and vaccines globally.  Over the analyzed period, MRK's cumulative return (63.68%) significantly underperformed the S&P 500's cumulative return (125.6%). The difference is -61.92%, placing its relative performance at the 5.21 percentile of its historical range (max: 47.45%, min: -67.93%).  This indicates MRK's performance has lagged behind the broader market considerably.

**Alpha/Beta Analysis:**

The provided data shows inconsistent alpha and beta values across different periods. While positive alpha (outperformance relative to the market) was observed in some years,  the most recent years show negative alpha, indicating underperformance relative to the market.  The beta consistently indicates that MRK is less volatile than the overall market (Beta < 1), although it has fluctuated over the years.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 8.2% | 15.6% | -30.2% | 0.9 | 135.8 |
| 2016-2018  | 59.7% | 15.6% | 27.4% | 0.7 | 184.4 |
| 2017-2019  | 65.0% | 15.6% | 13.3% | 0.7 | 219.5 |
| 2018-2020  | 58.9% | 25.8% | 11.6% | 0.7 | 197.4 |
| 2019-2021  | 16.7% | 25.8% | -83.3% | 0.6 | 193.9 |
| 2020-2022  | 39.4% | 25.8% | 15.8% | 0.5 | 280.7 |
| 2021-2023  | 55.2% | 19.5% | 20.2% | 0.3 | 275.8 |
| 2022-2024  | 35.8% | 25.6% | 6.9% | 0.3 | 244.3 |


**2. Recent Price Movement:**

* **Closing Price:** $96.54
* **5-Day Moving Average:** $97.25
* **20-Day Moving Average:** $101.36
* **60-Day Moving Average:** $109.39

The price is below all three moving averages, suggesting a downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (18.53):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.28):** Negative value suggests bearish momentum.
* **Relative Strength Change (20-day):** -16.88%, confirming a recent downtrend.

Given the current price of $96.54 is below the moving averages and RSI is oversold, it doesnâ€™t signal a dramatic price surge or crash. However, the low RSI suggests a potential upward correction could occur.  The expected return of 0.0% over the long term relative to the S&P 500 highlights the underperformance observed historically.

**4. Recent Financial Performance:**

The provided EPS and Revenue data shows some fluctuation.  While revenue generally increased, EPS showed some decline in recent quarters.  To provide a complete analysis, the financial reports containing details regarding earnings expectations would be necessary.


| Date       | EPS  | Revenue       |
|------------|------|----------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      |


**5.  Financial Information:**

The provided data on revenue and profitability shows strong revenue growth, with a high profit margin. However, there is fluctuation in Return on Equity (ROE),  indicating varied profitability performance across quarters.  Further analysis would require examining the drivers of ROE fluctuations.


**6. Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|----------------|
| 2024-09-30  | $16.66B     | 75.51%         |
| 2024-06-30  | $16.11B     | 76.76%         |
| 2024-03-31  | $15.78B     | 77.56%         |
| 2023-12-31  | $14.63B     | 73.26%         |
| 2023-09-30  | $15.96B     | 73.29%         |

**Capital and Profitability:**

| Quarter     | Equity      | ROE     |
|-------------|-------------|---------|
| 2024-09-30  | $44.50B     | 7.09%   |
| 2024-06-30  | $43.58B     | 12.52%  |
| 2024-03-31  | $40.36B     | 11.80%  |
| 2023-12-31  | $37.58B     | -3.26%  |
| 2023-09-30  | $41.25B     | 11.50%  |


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and FINBOLD.  Please provide recent news articles for a comprehensive analysis.)*  Analysis of recent news, including earnings calls, analyst opinions, and market outlook, is crucial for a complete assessment.


**8. Overall Summary:**

MRK has significantly underperformed the S&P 500 over the analyzed period. While it shows strong revenue and profit margins, recent EPS and ROE figures exhibit volatility.  Technical indicators suggest an oversold condition, hinting at potential short-term recovery. However, the long-term outlook requires considering news, analyst opinions, and a comprehensive assessment of the company's financial health and competitive landscape.  Further investigation into the reasons for underperformance relative to the market is warranted. The consistent low beta suggests lower volatility than the market, making it a potentially suitable component of a well-diversified portfolio for investors who can tolerate the underperformance compared to the S&P500.


**9. Disclaimer:** This analysis is based on the limited data provided.  It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough due diligence and consult with a financial advisor before making any investment choices.
